Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.
To continue reading click here
Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy
